Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting

Disease stabilization observed in patients with TTR amyloid cardiomyopathy Robust and sustained reductions in TTR protein observed in patients with familial amyloid polyneuropathy GSK to initiate a broad Phase 3 program in patients with TTR amyloid cardiomyopathy CARLSBAD, Calif., Nov. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive preliminary results from an ongoing investigator sponsored, open-label Phase 2 study in patients with TTR amyloid cardiomyopathy, which included patients with familial amyloid cardiomyopathy (FAC) and patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). In this study, patients receive one injection of ISIS-TTRRx once a week. The study will continue for 24 months. Data from patients treated for 12 months were presented today (abstract # PM14) by the lead investigator, Merrill D. Benson, M.D., at the First European Congress on Hereditary ATTR amyloidosis in Paris, France. Isis will review these data and the overall development plan for ISIS-TTRRx in a webcast scheduled for Tuesday, Nov. 3 at 8:00 a.m. Eastern Time.

The release as fetched from its publisher. ionis.com ↗